SCHEMBL1855593

SCHEMBL1855593

Cc1ccc(S(=O)(=O)Nc2cccc(CCCC(CCc3ccccc3)C(=O)O)c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 5/20 0.54
ALDH1A1 P00352 3/20 0.53
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49
KDM1A O60341 2/20 0.48
PTGES O14684 1/20 0.48
MEN1 O00255 1/20 0.48
GAA P10253 1/20 0.48
KMT2A Q03164 1/20 0.48
LIMK2 P53671 2/20 0.48
LIMK1 P53667 1/20 0.48
TCF4 P15884 1/20 0.47
CTNNB1 P35222 1/20 0.47
IKBKB O14920 1/20 0.47
MAOA P21397 1/20 0.46
MMP1 P03956 1/20 0.45
MMP2 P08253 1/20 0.45
MMP3 P08254 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1857288 0.91 HTR6 (0.51) HTR6ALDH1A1CA12CA1CA2
SCHEMBL8037792 0.91 HTR6 (0.51) HTR6ALDH1A1CA12CA1CA2
SCHEMBL1856441 0.88 HTR6 (0.53) HTR6ALDH1A1CA12CA1CA2
SCHEMBL8039484 0.88 HTR6 (0.58) HTR6MEN1KMT2ALIMK2LIMK1
SCHEMBL1860527 0.87 HDAC1 (0.54) HTR6MEN1KMT2ALIMK2LIMK1
SCHEMBL1858150 0.83 LIMK2 (0.54) ALDH1A1CA12CA9MEN1GAA
SCHEMBL12630239 0.82 NAMPT (0.45) HTR6ALDH1A1MEN1KMT2A
SCHEMBL1857972 0.81 NPC1 (0.49) HTR6ALDH1A1CA12CA9
SCHEMBL1856429 0.80 POLB (0.51) HTR6ALDH1A1MMP1MMP2MMP3
SCHEMBL1856417 0.79 MMP2 (0.54) ALDH1A1MMP1MMP2MMP3MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110105544-A1 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2011-05-05 US claimed
WO-2009080722-A2 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2009-07-02 WO claimed
US-20110105544-A1 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2011-05-05 US disclosed
US-20110105544-A1 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2011-05-05 US disclosed
US-20110105544-A1 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2011-05-05 US disclosed
WO-2009080722-A2 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2009-07-02 WO disclosed
WO-2009080722-A2 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105544-A1 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AKR1C3, TPD52L2, HCCS HTR6 3261/4885ALDH1A1 198/4885CA12 459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.